Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2009 Nov;9(11):1549-57. doi: 10.1586/era.09.124.

Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

Author information

1
Department of Oncology Hematology and Respiratory Diseases, University of Modena and Reggio Emilia University Hospital, Modena, Italy. guarneri.valentina@unimore.it

Abstract

Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2). Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy. Data from clinical trials are consistently showing the key role of this agent in the management of HER2-positive disease. Moreover, interesting data are suggesting a key role of lapatinib in enhancing endocrine responsiveness and/or restoring endocrine sensitivity in hormone receptor-positive disease. The present article will summarize the main data leading to the clinical development of the combination of lapatinib and the aromatase inhibitor letrozole.

PMID:
19895239
DOI:
10.1586/era.09.124
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center